» Authors » Joseph Conigliaro

Joseph Conigliaro

Explore the profile of Joseph Conigliaro including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 85
Citations 1866
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez L, Conigliaro J, Elnicki D
J Gen Intern Med . 2024 Dec; 40(3):515. PMID: 39625604
No abstract available.
2.
Wong C, Marrast L, Rasul R, Srivastava R, Kuvin J, Roswell R, et al.
PLoS One . 2024 Oct; 19(10):e0311724. PMID: 39378232
Background: There are disparities in statin therapy for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). The role of structural racism in this disparity has not been examined. Methods: This...
3.
Lopez L, Conigliaro J, Elnicki D
J Gen Intern Med . 2024 Aug; 39(13):2375-2377. PMID: 39117883
No abstract available.
4.
Conigliaro J, Elnicki D, Lopez L
J Gen Intern Med . 2024 Mar; 39(8):1286-1287. PMID: 38548936
No abstract available.
5.
Elnicki D, Conigliaro J, Lopez L
J Gen Intern Med . 2024 Mar; 39(6):889-890. PMID: 38467920
No abstract available.
6.
Elnicki M, Lopez L, Conigliaro J
J Gen Intern Med . 2023 Nov; 39(2):163-164. PMID: 37950106
No abstract available.
7.
Conigliaro J, Elnicki D, Lopez L
J Gen Intern Med . 2023 Oct; 39(1):1-2. PMID: 37848763
No abstract available.
8.
Hon J, Conigliaro J, Kim E
J Gen Intern Med . 2023 Oct; 39(1):3-4. PMID: 37848762
No abstract available.
9.
Brennan C, Nadella S, Zhao X, Dima R, Jordan-Martin N, Demestichas B, et al.
Gut . 2022 Feb; 71(5):879-888. PMID: 35144974
Objective: We assessed whether famotidine improved inflammation and symptomatic recovery in outpatients with mild to moderate COVID-19. Design: Randomised, double-blind, placebo-controlled, fully remote, phase 2 clinical trial (NCT04724720) enrolling symptomatic...
10.
Houston T, Chen J, Amante D, Blok A, Nagawa C, Wijesundara J, et al.
JAMA Intern Med . 2022 Jan; 182(3):303-312. PMID: 35072714
Importance: Most trials of behavioral or pharmaceutical interventions for people who smoke are limited to individuals reporting they are ready to quit smoking. Engaging individuals who initially report they are...